Osteopontin-Stimulated Expression of Matrix Metalloproteinase-9 Causes Cardiomyopathy in the mdx Model of Duchenne Muscular Dystrophy
暂无分享,去创建一个
[1] K. Flanigan. The Muscular Dystrophies , 2012, Seminars in Neurology.
[2] D. Denhardt,et al. Osteopontin: role in immune regulation and stress responses. , 2011, Cytokine & growth factor reviews.
[3] A. Nakamura,et al. Matrix metalloproteinase-2 ablation in dystrophin-deficient mdx muscles reduces angiogenesis resulting in impaired growth of regenerated muscle fibers. , 2011, Human molecular genetics.
[4] F. Beau,et al. A Selective Matrix Metalloproteinase-12 Inhibitor Retards Atherosclerotic Plaque Development in Apolipoprotein E–Knockout Mice , 2011, Arteriosclerosis, thrombosis, and vascular biology.
[5] S. Tyagi,et al. Attenuation of beta2-adrenergic receptors and homocysteine metabolic enzymes cause diabetic cardiomyopathy. , 2010, Biochemical and biophysical research communications.
[6] S. Bhatnagar,et al. Matrix metalloproteinase inhibitor batimastat alleviates pathology and improves skeletal muscle function in dystrophin-deficient mdx mice. , 2010, The American journal of pathology.
[7] M. Klapholz,et al. Osteopontin in Cardiovascular Disease: A Potential Therapeutic Target , 2010, Cardiology in review.
[8] S. Tyagi,et al. Folic Acid Mitigated Cardiac Dysfunction by Normalizing the Levels of Tissue Inhibitor of Metalloproteinase and homocysteine‐metabolizing enzymes Post myocardial Infarction in Mice. , 2010, American journal of physiology. Heart and circulatory physiology.
[9] S. Bhatnagar,et al. Therapeutic targeting of signaling pathways in muscular dystrophy , 2010, Journal of Molecular Medicine.
[10] Shing-Hwa Liu,et al. Osteopontin increases migration and MMP‐9 up‐regulation via αvβ3 integrin, FAK, ERK, and NF‐κB‐dependent pathway in human chondrosarcoma cells , 2009, Journal of cellular physiology.
[11] S. Bhatnagar,et al. Matrix metalloproteinase-9 inhibition ameliorates pathogenesis and improves skeletal muscle regeneration in muscular dystrophy. , 2009, Human molecular genetics.
[12] E. Hoffman,et al. Osteopontin promotes fibrosis in dystrophic mouse muscle by modulating immune cell subsets and intramuscular TGF-beta. , 2009, The Journal of clinical investigation.
[13] Ashok Kumar,et al. TNF-Like Weak Inducer of Apoptosis (TWEAK) Activates Proinflammatory Signaling Pathways and Gene Expression through the Activation of TGF-β-Activated Kinase 11 , 2009, The Journal of Immunology.
[14] S. Tyagi,et al. Tumor Necrosis Factor-related Weak Inducer of Apoptosis Augments Matrix Metalloproteinase 9 (MMP-9) Production in Skeletal Muscle through the Activation of Nuclear Factor-κB-inducing Kinase and p38 Mitogen-activated Protein Kinase , 2009, Journal of Biological Chemistry.
[15] James J. Lee,et al. Major basic protein-1 promotes fibrosis of dystrophic muscle and attenuates the cellular immune response in muscular dystrophy. , 2008, Human molecular genetics.
[16] S. Matecki,et al. L-arginine decreases inflammation and modulates the nuclear factor-kappaB/matrix metalloproteinase cascade in mdx muscle fibers. , 2008, The American journal of pathology.
[17] K. Yutzey,et al. Regulation of Cardiomyocyte Proliferation and Myocardial Growth During Development by FOXO Transcription Factors , 2008, Circulation research.
[18] B. Fingleton. MMPs as therapeutic targets--still a viable option? , 2008, Seminars in cell & developmental biology.
[19] J. Raffetto,et al. Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease. , 2008, Biochemical pharmacology.
[20] A. Kurata,et al. Serum matrix metalloproteinase-3 as a novel marker for risk stratification of patients with nonischemic dilated cardiomyopathy. , 2007, Journal of cardiac failure.
[21] X. Wang,et al. An osteopontin fragment is essential for tumor cell invasion in hepatocellular carcinoma , 2007, Oncogene.
[22] Jialiang Hu,et al. Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases , 2007, Nature Reviews Drug Discovery.
[23] K. L. Gardner,et al. Interplay of IKK/NF-kappaB signaling in macrophages and myofibers promotes muscle degeneration in Duchenne muscular dystrophy. , 2007, The Journal of clinical investigation.
[24] Andrew J. Ewald,et al. Matrix metalloproteinases and the regulation of tissue remodelling , 2007, Nature Reviews Molecular Cell Biology.
[25] C. Dogra,et al. Regulation of phosphatidylinositol 3‐kinase (PI3K)/Akt and nuclear factor‐kappa B signaling pathways in dystrophin‐deficient skeletal muscle in response to mechanical stretch , 2006, Journal of cellular physiology.
[26] J. Tidball,et al. Damage and inflammation in muscular dystrophy: potential implications and relationships with autoimmune myositis , 2005, Current opinion in rheumatology.
[27] Jason L. Johnson,et al. Divergent effects of matrix metalloproteinases 3, 7, 9, and 12 on atherosclerotic plaque stability in mouse brachiocephalic arteries , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[28] J. Tidball,et al. Cardiomyopathy in dystrophin-deficient hearts is prevented by expression of a neuronal nitric oxide synthase transgene in the myocardium. , 2005, Human molecular genetics.
[29] S. Cobbold,et al. Effects of T-lymphocyte depletion on muscle fibrosis in the mdx mouse. , 2005, The American journal of pathology.
[30] K. Davies,et al. Dystrophin‐ and MLP‐deficient mouse hearts: marked differences in morphology and function, but similar accumulation of cytoskeletal proteins , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[31] Z. Werb,et al. Regulation of matrix biology by matrix metalloproteinases. , 2004, Current opinion in cell biology.
[32] G. Kundu,et al. Nuclear Factor-inducing Kinase Plays a Crucial Role in Osteopontin-induced MAPK/IκBα Kinase-dependent Nuclear Factor κB-mediated Promatrix Metalloproteinase-9 Activation* , 2004, Journal of Biological Chemistry.
[33] B. Wong,et al. Evolution of the mdx mouse cardiomyopathy: physiological and morphological findings , 2004, Neuromuscular Disorders.
[34] E. McNally,et al. The dystrophin glycoprotein complex: signaling strength and integrity for the sarcolemma. , 2004, Circulation research.
[35] Ashok Kumar,et al. Loss of dystrophin causes aberrant mechanotransduction in skeletal muscle fibers , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[36] E. Engvall,et al. The new frontier in muscular dystrophy research: booster genes , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[37] K. Davies,et al. Pharmacological strategies for muscular dystrophy , 2003, Nature Reviews Drug Discovery.
[38] Ashok Kumar,et al. Mechanical stress activates the nuclear factor‐kappaB pathway in skeletal muscle fibers: a possible role in Duchenne muscular dystrophy , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[39] M. Wheeler,et al. Cytoskeletal defects in cardiomyopathy. , 2003, Journal of molecular and cellular cardiology.
[40] A. Nakamura,et al. Progression of dystrophic features and activation of mitogen‐activated protein kinases and calcineurin by physical exercise, in hearts of mdx mice , 2002, FEBS letters.
[41] T. Rando. The dystrophin–glycoprotein complex, cellular signaling, and the regulation of cell survival in the muscular dystrophies , 2001, Muscle & nerve.
[42] L. Matrisian,et al. Matrix metalloproteinases: they're not just for matrix anymore! , 2001, Current opinion in cell biology.
[43] J. Tidball,et al. Do immune cells promote the pathology of dystrophin-deficient myopathies? , 2001, Neuromuscular Disorders.
[44] M. Rudnicki,et al. Activation of JNK1 contributes to dystrophic muscle pathogenesis , 2001, Current Biology.
[45] A. Nakamura,et al. Activation of calcineurin and stress activated protein kinase/p38-mitogen activated protein kinase in hearts of utrophin–dystrophin knockout mice , 2001, Neuromuscular Disorders.
[46] G. Danieli,et al. Heart transplantation in patients with inherited myopathies associated with end-stage cardiomyopathy: molecular and biochemical defects on cardiac and skeletal muscle. , 2001, Transplantation proceedings.
[47] J. Tidball,et al. Helper (CD4(+)) and cytotoxic (CD8(+)) T cells promote the pathology of dystrophin-deficient muscle. , 2001, Clinical immunology.
[48] E. Ohlstein,et al. Matrix metalloproteinase expression in cardiac myocytes following myocardial infarction in the rabbit. , 2001, Life sciences.
[49] J. Woessner,et al. Matrix metalloproteinases and collagen ultrastructure in moderate myocardial ischemia and reperfusion in vivo. , 2000, American journal of physiology. Heart and circulatory physiology.
[50] P. Libby,et al. Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. , 2000, The Journal of clinical investigation.
[51] I. Stamenkovic,et al. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. , 2000, Genes & development.
[52] P Bacchetti,et al. Serum MMP-9 and TIMP-1 levels are related to MRI activity in relapsing multiple sclerosis. , 1999, Neurology.
[53] G. Radda,et al. Decreased myocardial nNOS, increased iNOS and abnormal ECGs in mouse models of Duchenne muscular dystrophy. , 1999, Journal of molecular and cellular cardiology.
[54] E. Hoffman,et al. Heart involvement in muscular dystrophies due to sarcoglycan gene mutations , 1999, Muscle & nerve.
[55] J. Towbin,et al. Etiologies of cardiomyopathy and heart failure , 1999, Nature Medicine.
[56] D. Mann,et al. Activation of matrix metalloproteinases in the failing human heart: breaking the tie that binds. , 1998, Circulation.
[57] Y. Sun,et al. Differential expression of tissue inhibitors of metalloproteinases in the failing human heart. , 1998, Circulation.
[58] M. Fardeau,et al. Matrix metalloproteinases MMP‐2 and MMP‐9 in denervated muscle and injured nerve , 1998, Neuropathology and applied neurobiology.
[59] H. Wiggers,et al. Increased amounts of collagenase and gelatinase in porcine myocardium following ischemia and reperfusion. , 1998, Journal of molecular and cellular cardiology.
[60] K. Campbell,et al. Animal Models for Muscular Dystrophy Show Different Patterns of Sarcolemmal Disruption , 1997, The Journal of cell biology.
[61] J. Tidball,et al. Myonuclear apoptosis in dystrophic mdx muscle occurs by perforin-mediated cytotoxicity. , 1997, The Journal of clinical investigation.
[62] A. Beggs. Dystrophinopathy, the expanding phenotype. Dystrophin abnormalities in X-linked dilated cardiomyopathy. , 1997, Circulation.
[63] L. Kunkel,et al. Dystrophies and heart disease. , 1997, Current opinion in cardiology.
[64] S. Chandler,et al. Matrix metalloproteinases, tumor necrosis factor and multiple sclerosis: an overview , 1997, Journal of Neuroimmunology.
[65] S. Kumar,et al. Post-transcriptional regulation of extracellular matrix metalloproteinase in human heart end-stage failure secondary to ischemic cardiomyopathy. , 1996, Journal of molecular and cellular cardiology.
[66] L. Liotta,et al. Modulation of type‐iv collagenase activity and invasive behavior of metastatic human melanoma (A2058) cells in vitro by monoclonal antibodies to type‐iv collagenase , 1990, International journal of cancer.
[67] L. Politano,et al. The incidence and evolution of cardiomyopathy in Duchenne muscular dystrophy. , 1990, International journal of cardiology.
[68] E A Barnard,et al. The molecular basis of muscular dystrophy in the mdx mouse: a point mutation. , 1989, Science.
[69] L. Liotta,et al. Expression of collagenase IV (basement membrane collagenase) activity in murine tumor cell hybrids that differ in metastatic potential. , 1985, Journal of the National Cancer Institute.
[70] K. Frankel,et al. The pathology of the heart in progressive muscular dystrophy: epimyocardial fibrosis. , 1976, Human pathology.
[71] A. Feldman,et al. Matrix Metalloproteinases in the Progression of Heart Failure , 2012, Drugs.
[72] R. Kizek,et al. Matrix metalloproteinases. , 2010, Current medicinal chemistry.
[73] S. Slater,et al. MMP-9 and -12 cause N-cadherin shedding and thereby beta-catenin signalling and vascular smooth muscle cell proliferation. , 2009, Cardiovascular research.
[74] B. Fingleton,et al. Matrix metalloproteinases as valid clinical targets. , 2007, Current pharmaceutical design.
[75] W. Miller,et al. A look between the cardiomyocytes: the extracellular matrix in heart failure. , 2006, Mayo Clinic proceedings.
[76] G. Kundu,et al. Nuclear factor-inducing kinase plays a crucial role in osteopontin-induced MAPK/IkappaBalpha kinase-dependent nuclear factor kappaB-mediated promatrix metalloproteinase-9 activation. , 2004, The Journal of biological chemistry.
[77] S. Lachkar,et al. Expression of matrix metalloproteinases 2 and 9 in regenerating skeletal muscle: a study in experimentally injured and mdx muscles. , 1999, Developmental biology.